Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
E.l.f. Beauty Insider Sold Shares Worth $4,855,661, According to a Recent SEC Filing

E.l.f. Beauty Insider Sold Shares Worth $4,855,661, According to a Recent SEC Filing

MT newswireMT newswire2026/10/05 20:37

04:37 PM EDT, 10/05/2026 (MT Newswires) -- Tarang Amin, Director, Chief Executive Officer, on October 01, 2026, sold 47,000 shares in E.l.f. Beauty (ELF) for $4,855,661. Following the Form 4 filing with the SEC, Amin has control over a total of 1,307,402 common shares of the company, with 134,496 shares held directly and 1,172,906 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1600033/000161071726000425/xslF345X05/form4.xml

04:37 PM EDT, 10/05/2026 (MT Newswires) -- Tarang Amin, Director, Chief Executive Officer, on October 01, 2026, sold 47,000 shares in E.l.f. Beauty (ELF) for $4,855,661. Following the Form 4 filing with the SEC, Amin has control over a total of 1,307,402 common shares of the company, with 134,496 shares held directly and 1,172,906 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1600033/000161071726000425/xslF345X05/form4.xml
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks

Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.

智通财经•2026/10/26 03:41
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks